GammaRips
Back to Signals

MRNA

BEAR
2026-05-19

Overnight Institutional Flow Signal

Score
6/10
Move
1.6%
Flow
$7.3M
AI Trade Thesis
MRNA BEAR $48.5P May 29 '26. Capitalize on the exhaustion of the recent 20% non-fundamental surge as price action breaks below the $48.40 insider selling level. Target a move toward the primary support at $44.37 as the stock returns to its pre-rally valuation. Risk: Positive clinical trial updates or regulatory news regarding the mCOMBRIAX combination vaccine.
Flow Breakdown
Call Volume
$2.6M
Put Volume
$4.7M
Flow Intent
DIRECTIONAL
Catalyst
Insider Activity
Recommended Setup
ContractO:MRNA260529P00048500
Contract Score10.839/10
Risk/Reward1.4:1
Delta-0.50
Key Levels
Resistance$51.27
Support$43.68
Price$48.11
SMA 50 / 200$51 / $37
52W Range$22$60
News & Catalyst Analysis

Key Headline

Moderna President Stephen Hoge Sells 53,336 Shares as Hantavirus-Driven Momentum Exhausts

News Summary

MRNA is experiencing a momentum reversal as the speculative rally triggered by hantavirus headlines fades and analysts dismiss the news as fundamentally non-material. Institutional bearish flow is intensifying following an SEC filing showing the company President sold over $2.5M worth of shares near the $48.40 level, signaling a potential local ceiling.

Flow Intent Analysis

The $4.6M flow appears to be an aggressive bet on a continued pullback following a sentiment-driven spike, rather than a hedge for the minor -1.6% daily move.

One email a week. Catch up in five minutes.

The GammaRips weekly briefing — engine state, the latest deep-dive, and the picks on the public ledger. No firehose, no FOMO.

Free weekly newsletter. No spam. Unsubscribe anytime.

One email a week. Catch up in five minutes.

The GammaRips weekly briefing — engine state, the latest deep-dive, and the picks on the public ledger. No firehose, no FOMO.

Free weekly newsletter. No spam. Unsubscribe anytime.

    We Use Cookies

    We use cookies to enhance your experience, analyze site traffic, and for marketing purposes. By clicking "Accept," you agree to our use of cookies. Read our Privacy Policy.